Home
Apogee Therapeutics

Apogee Therapeutics Market Share Analysis for June 2026

Apogee Therapeutics is a clinical stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immune (I&I) diseases with high unmet need

Health > Biotechnology and Pharmaceuticals

Domainapogeetherapeutics.com

Year Founded2022

Employees201 - 500

Annual Revenue--

Apogee Therapeutics

Apogee Therapeutics (including company regionals)

apogeetherapeutics.com

See more website traffic and engagement information

Total visits to Apogee Therapeutics's top domains

Understand Apogee Therapeutics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

apogeetherapeutics.com40.8K

See more with Sales Intelligence

Avg. visit duration in Apogee Therapeutics's top domains

Analyze Apogee Therapeutics engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

apogeetherapeutics.com00:02:36

See more with Sales Intelligence

Avg. pageviews on Apogee Therapeutics's top domains

See how Apogee Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

apogeetherapeutics.com3.53

See more with Sales Intelligence

Apogee Therapeutics top competitors by domain

Top similar sites in June 2026, ranked by their affinity

tubulis.comCompany NameTubulis GmbHEmployees51 - 200HQGermany, MunichAnnual revenue$75M - $100MTotal visits8.6KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Apogee Therapeutics

These are the website technologies, by industry, used by Apogee Therapeutics top domains

Content Management System (3)

Netlify

Marketing (3)

Google Marketing Platform

Conversion & Analytics (2)

Google Analytics

Mobile (2)

Meta Viewport

More Technologies

6

See all

News & Signals from Apogee Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsApogee Therapeutics, LLC sold assets to AbbVie Inc. in the amount of $10.9B on Jun 22nd '26.AbbVie will acquire Apogee's pipeline of clinical-stage drug candidates for inflammatory and immune-related diseases, including atopic dermatitis and asthma.

NewsApogee Therapeutics, LLC received financing of $1.3B in financing on May 1st '26.In May, Apogee secured up to $1.3 billion in financing from Blackstone Life Sciences to fund a Phase 3 trial and a potential launch without selling more stock.

NewsApogee Therapeutics, LLC received financing of $800M in synthetic royalty funding on Jun 17th '26.The transaction is structured to provide Apogee with an optimal cost of capital by pairing up to $800 million in synthetic royalty funding with up to $500 million in senior corporate debt, which is accessible via mutual consent.